The Annual General Meeting of Evotec SE will be held on Monday, 10 June 2024, at 10.00 a.m. (CEST), at CinemaxX Hamburg-Dammtor, Room 1, Dammtordamm 1, 20354 Hamburg, Germany as an in-person event.

If you wish to view our Annual General Meeting archive you can do so here.

1. Presentation of the approved separate annual financial statements and the consolidated financial statements of Evotec SE as of 31 December 2023, as approved by the Supervisory Board, the management reports for Evotec SE and for the Group for the 2023 financial year, the report of the Supervisory Board for the 2023 financial year, and the explanatory report by the Management Board regarding this information pursuant to Sections 289a, 315a of the German Commercial Code (HGB) for the 2023 financial year
2. Resolution discharging the members of the Management Board of liability for the 2023 financial year
3. Resolution regarding formal approval of the actions of the members of the Supervisory Board for the 2023 financial year
4. Resolution regarding the appointment of the auditor for the separate financial statements and the consolidated financial statements for the 2024 financial year, and the appointment of the auditor for any review of additional financial information during the year
5. Resolution to approve the Remuneration Report 2023
6. Resolution concerning the creation of new authorised capital with the possibility to exclude subscription rights and amendment of Article 5 (5) of the Articles of Association (Authorised Capital 2024)
7. Resolution on amendments to the Articles of Association to adjust the terms of office, the requirements for the election of the Chairman of the Supervisory Board and his deputy and the remuneration of the Supervisory Board
       7.1. Terms of office of the Supervisory Board members
       7.2. Election of the Chairman of the Supervisory Board and his deputy
       7.3. Supervisory Board remuneration
8. Resolution concerning new elections to the Supervisory Board
       8.1. Prof. Dr. Iris Löw-Friedrich, Ratingen, Germany, Chief Medical Officer of UCB S.A. based in Brussels, Belgium
       8.2. Mr Roland Sackers, Cologne, Germany, Chief Financial Officer and Managing Director of QIAGEN N.V., Venlo, Netherlands
       8.3. Ms. Camilla Macapili Languille, Abu Dhabi, United Arab Emirates, Head of Life Sciences, Mubadala Investment Company, based in Abu Dhabi
       8.4. Dr Constanze Ulmer-Eilfort, Munich, Germany, partner at law firm Peters, Schönberger & Partner, based in Munich, Germany
       8.5. Dr Duncan McHale, London, UK, founder and director of Weatherden Ltd., based in London, UK.
       8.6. Mr. Wesley Wheeler, Chapel Hill, USA, Member of the Board of Directors at Envirotainer AB, headquartered in Sollentuna, Sweden
9. Resolution on the amendment of Section 15 Paragraph 4 Sentence 6 of the Articles of Association (record date)

• Convening and Agenda of the Annual General Meeting, PDF
• Information pursuant to § 125 para. 1 AktG in conjunction with. §125 para. 5 AktG, Article 4 para. 1 as well as Table 3 of the Annex to the Implementing Regulation (EU) 2018/1212, PDF
• Annual Report 2023, PDF
• Annual financial statements 2023, PDF
• Corporate governance declaration for the 2023 financial year, PDF
• Information on agenda item 4 “Appointment of the auditor, the Group auditor for the 2024 financial year and the auditor for the review of additional interim financial information”, PDF
• Remuneration report 2023 on agenda item 5, PDF
• Report of the Management Board on agenda item 6, PDF
• Remuneration system for members of the Supervisory Board on agenda item 7.3, PDF
• CVs of the Supervisory Board candidates on agenda item 8, PDF
• Articles of Association Evotec SE, PDF
• Explanatory notes on the resolutionless item 1, PDF
• Explanation of shareholders' rights, PDF
• Total number of shares and voting rights at the time of convening the Annual General Meeting, PDF

• Power of attorney to the proxies of the Company, PDF
• Proxy to a third person, PDF
• Revocation of proxy, PDF

• Data Protection Information for Shareholders, PDF

There are currently no countermotions.

LOGIN to the password-protected internet service for granting a power of attorney to a third person as well as for granting power of attorney and issuing instructions to the proxies appointed by the Company and to follow the transmission of the Annual General Meeting.
The personal access data required for this purpose will be sent to the shareholders or their proxies after registration for the Annual General Meeting.
In case of later (sub-)authorisation, the following applies: The use of the password-protected internet service by the proxy requires that the proxy receives the corresponding access data.
A power of attorney to a third person as well as a power of attorney with instructions to the proxies of the Company may be granted, amended or revoked via the password-protected internet service until 24:00 (CEST) on 9 June 2024.

The Company plans to broadcast the opening of the Annual General Meeting by the chair of the meeting and the speech by the Management Board live for registered shareholders or their proxies on the password-protected internet service on 10 June 2024 from 10.00 a.m. CEST onwards live in picture and sound.

Confirmation of the vote count pursuant to section 129 (5) sentence 1 AktG

Pursuant to section 129 (5) sentence 1 of the German Stock Corporation Act (AktG), the person voting may request confirmation from the company within one month of the day of the Annual General Meeting as to whether and how his or her vote was counted. A request to this effect may be sent by e-mail to: evotec@linkmarketservices.eu 

Hotline

Monday to Friday from 9 am to 5 pm by phone on +49 (0)89 8896906 610

Contact AGM Team

Evotec SE

Anja Ben Lekhal

Investor Relations Advisor

Manfred Eigen Campus

Essener Bogen 7

22419 Hamburg

T: +49 151 5187 1069

hauptversammlung@evotec.com 

Contact to the ADR Program

JPMorgan Chase & Co.

P.O. Box 64504

St. Paul, MN 55164-0504

USA

T: 800.990 1135 (from inside the USA)

T: +1.651.453 2128 (from outside the USA)

jpmorgan.adr@eq-us.com